Biomarkers for disease assessment

CLS partners with pharmaceutical and biotechnology companies to validate biomarkers for disease assessment and targeted therapeutic development in cancer and other diseases.

Portrait of a female scientist in goggles looking under a microscope at samples.

Targeted therapeutic development

CLS partners with pharmaceutical and biotechnology companies to validate biomarkers for disease assessment and targeted therapeutic development in a range of cancers. These partnerships also provide the foundation for CLS to develop companion diagnostic/prognostic tests in conjunction with partners’ targeted therapeutics. CLS also pursues internal programs to develop proprietary diagnostic tests in specific areas of cancer management.

The approach is based on identifying circulating molecular markers generated by tumor cells in the peripheral blood of patients with neoplasia to assess disease, recurrence, progression and response to therapy.

Breast Cancer (BRCA)

Screening programs for the identification of early stage BRCA can significantly improve patient outcome because of the treatment benefit of early detection. In addition, accurate markers for treatment responses (disease recurrence) can refocus treatment approaches in a timely fashion based upon sensitive detection of treatment efficacy.

Colon Cancer (COAD)

Screening programs for the identification of early stage CRC and pre-neoplastic conditions can significantly improve disease outcome.

Lung Cancer (LUAD)

Screening for early stage LUAD can improve disease outcomes, help define treatment pathways and provide a tool to monitor surgical and therapeutic interventions.

Ovarian Cancer (OV)

This is extremely difficult to diagnose and is often detected at a late stage with metastatic spread. Early, accurate diagnosis is critical and tools are required for early detection.

Prostate Cancer (PRAD)

Identification of patients with a poor prognosis or predicting who will respond to therapies including ADT and 177Lu-PSMA-therapy will facilitate stratification of those likely to benefit from specific treatment regimens. Molecular markers that are predictive and prognostic will benefit management potentially extending survival and reducing unwanted therapeutic side-effects.

Pancreatic Cancer (PAAD)

Early pancreatic cancer is often asymptomatic. Diagnosis rarely occurs until disease is advanced thus survival is limited. PCR-based blood tests for pancreatic cancer identification and assessment of treatment response provide much-needed tools. These will enable detection of early disease prior to symptom development and facilitate disease monitoring.

Melanoma (SKCM)

There are currently no effective circulating diagnostic or prognostic biomarkers. Molecular biomarkers that can be used to monitor the efficacy of surgery or identify whether immunotherapies are effective are key tools. Early detection of recurrent disease or the ability to accurately determine response (or lack thereof) to a therapy can significantly improve disease outcome.

Multiple Myeloma

Accurate determination of minimal residual disease and identification of individuals who may relapse is a critical unmet need. Early detection of changes in clonality or molecular markers of poor prognosis can significantly improve management and extend survival.

Neuroendocrine Cancers

The NETest is an established, validated blood test that functions both as a “rule-out” diagnostic test (to confirm absence of a tumor or residual disease) and as prognostic test to measure therapeutic responses to individual treatments. The NETest is also effective in the identification of neuroendocrine differentiation in lung and prostate cancers.

Medical research scientist conducts DNA experiments under a digital microscope in a biological applied science laboratory.

Wren Laboratories, Our CLIA Laboratory

Please visit Wren Laboratories for more information on our CLIA laboratory facility in Branford, CT which processes our tests and conducts research and development in the USA.

Customers are thrilled with the results we have achieved.

Abstract genome sequence and chromosome architecture map.